610.86
610.86 (0%)
As of Apr 28, 2025
Regeneron Pharmaceuticals, Inc. [REGN]
Source:
Company Overview
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.
| Country | United States |
| Headquarters | tarrytown, new york |
| Phone Number | (914) 847-7000 |
| Industry | manufacturing |
| CEO | Leonard S. Schleifer |
| Website | www.regeneron.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $14,202 |
| Operating Profit | $3,990.7 |
| Net Income | $4,412.6 |
| Net Cash | $-248.8 |
Profit Ratios
| Gross Margin | $14,202 |
| Operating Margin | 28.1 |
| Profit as % of Revenues | 321.9% |
| Profit as % of Assets | 12.5% |
| Profit as % of Stockholder Equity | 15% |
Management Effectiveness
| Return on Equity | 15% |
| Return on Assets | 11.7% |
| Turnover Ratio | 40.1% |
| EBITA | $3,990.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $37,759.4 |
| Total Liabilities | $8,405.8 |
| Operating Cash Flow | $4,420.5 |
| Investing Cash Flow | $-2,468.1 |
| Financing Cash Flow | $-2,200.5 |
